Literature DB >> 22554491

Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.

Graziana Lupattelli1, Donatella Siepi, Stefano De Vuono, Anna Rita Roscini, Federica Crisanti, Domenico Covelli, Matteo Pirro, Elmo Mannarino.   

Abstract

AIM: Non-cholesterol sterols reflect cholesterol metabolism. Statins reduce cholesterol synthesis usually with a rise in cholesterol absorption. Common hyperlipemias have shown different patterns of cholesterol metabolism. We evaluated whether cholesterol absorption and synthesis may differ after statin therapy in primary hyperlipemias. MAIN
METHODS: We determined lipid profile, apoprotein B and serum sterols (lathosterol, sitosterol, campesterol by gas chromatography/mass spectrometry) before and after statins in 80 untreated hyperlipemic patients, 40 with polygenic hypercholesterolemia (PH) and 40 with familial combined hyperlipemia (FCH). KEY
FINDINGS: At baseline in FCH lathosterol was significantly higher while campesterol and sitosterol were significantly lower than in PH. After statins, the reduction in LDL-C did not significantly differ between the two groups; in PH there was a significant decrease of lathosterol from 96.1 to 52.6 102 μmol/mmol cholesterol (p=0.0001) with no significant modifications in campesterol and sitosterol; on the opposite, in FCH lathosterol decreased from 117 to 43 102 μmol/mmol cholesterol (p=0.0001) and campesterol and sitosterol significantly increased from 38 to 48 102 μmol/mmol cholesterol (p=0.0001), and from 75 to 86 102 μmol/mmol cholesterol, (p=0.022), respectively. After statin therapy only in FCH Δ-LDL-C showed a significant inverse correlation with Δ-sitosterol and with Δ-campesterol. SIGNIFICANCE: Primary hyperlipemias show different patterns of response to statins: in PH LDL reduction appears completely "synthesis inhibition" dependent, while in FCH LDL decrease appears to be synthesis dependent, partially limited by absorption increase. Studying cholesterol metabolism before and after hypolipemic therapy might be useful in identifying the best tailored treatment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554491     DOI: 10.1016/j.lfs.2012.03.038

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.

Authors:  Eric J Niesor; David Kallend; Darren Bentley; John J P Kastelein; G Kees Hovingh; Erik S G Stroes
Journal:  Lipids       Date:  2014-10-04       Impact factor: 1.880

2.  Pomegranate for your cardiovascular health.

Authors:  Michael Aviram; Mira Rosenblat
Journal:  Rambam Maimonides Med J       Date:  2013-04-30

3.  A pilot study of the effect of ezetimibe for postprandial hyperlipidemia.

Authors:  En-Zhong Xue; Ming-Hui Zhang; Chun-Li Liu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

4.  Deep Learning-Based Method of Diagnosing Hyperlipidemia and Providing Diagnostic Markers Automatically.

Authors:  Yuliang Liu; Quan Zhang; Geng Zhao; Guohua Liu; Zhiang Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-11       Impact factor: 3.168

5.  Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population.

Authors:  Marco Bertolotti; Chiara Mussi; Elisa Pellegrini; Alessandro Magni; Marina Del Puppo; Silvia Ognibene; Lucia Carulli; Claudia Anzivino; Enrica Baldelli; Paola Loria; Nicola Carulli
Journal:  Clin Interv Aging       Date:  2014-03-17       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.